Rossari Biotech

Quick check

The five things to look at first. Open one for more.

• DebtHigh safetyRated AA- by ICRA.
• ResultsGrowingIn the Sep 2026 quarter, sales rose 19% and profit rose 5.4% from a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersSteadyThe promoters (founders or parent) own 68% of the company, about the same as in Sep 2025.
• ValuationCheap vs its pastThe share trades at 14.8 times its yearly earnings (P/E), cheaper than 100% of the time in the last 5 years. Its usual P/E is about 37.

Rossari Biotech against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)14.8 against a typical 25.8: cheaper than most peers (1st = cheapest).35th of 129
• Sales growth+19.1% against a typical +25.9% from a year earlier.72nd of 112
• Profit growth+5.4% against a typical +42.4% from a year earlier.76th of 102
• Share price, 3 months−18.8% against a typical −5.8%.102nd of 118
• Size₹ 2,299.1 Cr. market value against a typical ₹ 359.6 Cr. (1st = largest).33rd of 126

Exchange filings and their impact on the company.

• 22 Oct 2026Analysts/Institutional Investor Meet/Con. Call UpdatesMedium impactPositivePrice −3% on 23 Oct
  Rossari posted record Q2 revenue and EBITDA with strong exports and debt reduction while advancing Thailand and Saudi expansion.

  Rossari Biotech reported its highest-ever quarterly revenue of Rs 697.6 crore, up 19%, and EBITDA of Rs 87 crore, up 21%, with margins at 12.5% led by HPPC, textiles and exports at 31% of sales. The institutional and B2C business turned EBITDA positive, net debt fell to Rs 221 crore from Rs 281 crore in March, and working capital improved to 86 days. Management guided mid-to-high teen revenue growth with ~12% EBITDA for FY27, expects Reliance ethylene oxide relief from Q1 next year, and approved leasing land for a greenfield plant in Saudi Arabia.

  Full analysisFiling
• 17 Oct 2026General UpdatesMedium impactPositivePrice −3.8% on 19 Oct
  Strong 19% revenue growth with steady profits, plus first step toward a Saudi greenfield plant.

  Rossari Biotech reported Q2 FY27 consolidated revenue of Rs 697.6 crore, up about 19% from last year, with net profit of Rs 38.9 crore, up about 5.5%. For the first half, revenue was Rs 1394.8 crore with operating cash flow of Rs 131.4 crore and borrowings reduced to Rs 361.8 crore. The board also approved leasing of land by its wholly owned subsidiary Rossari International Company for a greenfield plant in Saudi Arabia, with investment details to be decided later.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Edward Menezes

Executive Chairman of the Board, Co-Founder

Sunil Srinivasan Chari

Managing Director, Co-Founder, Executive Director

Ketan Sablok

Group Chief Financial Officer

Parul Gupta

Head- Company Secretary & Legal